Enavogliflozin (Synonyms: DWP-16001) |
カタログ番号GC64266 |
抗糖尿病薬であるエナボグリフロジン (DWP-16001) は、経口活性でクラス最高の選択的ナトリウム-グルコース共輸送体-2 (SGLT-2) 阻害剤です 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1415472-28-4
Sample solution is provided at 25 µL, 10mM.
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
[1]. Daewoong speeds up developing antidiabetic Enavogliflozin
[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin
[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong’s Enavogliflozin & Janssen Biotech’s Golimumab Among Others - ResearchAndMarkets.com
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *